siRNA Library Screening to Identify Complementary Therapeutic Pairs in Triple-Negative Breast Cancer Cells

  • Bindu Thapa
  • KC Remant
  • Hasan UludağEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)


The existence of tightly integrated cross talk through multiple signaling and effector pathways has been appreciated in malignant cells. The realization of the plasticity of such networks is stimulating the development of combinational therapy to overcome the limitations of one-dimensional therapies. Synergistic pairs of siRNAs or siRNA and drug combinations are the new frontiers in identifying effective therapeutic combinations. To elucidate effective combinations, we developed a versatile protocol to screen siRNA libraries in triple-negative breast cancer cell models. This protocol outlines the steps to identify synergistic combinations of siRNA-siRNA or siRNA-drug combinations using siRNA libraries via a robotic screen. By focusing on smaller functional siRNA libraries, we present methodologies to identify synergistic siRNA pairings against cancerous cell growth and molecular targets to augment the activity of pro-apoptotic TRAIL protein. Here, we summarize the critical steps to undertake such combinational target identification, emphasizing critical factors that affect the outcome of the screens. Our experience suggests that siRNA library screening is an efficient protocol to identify complementary therapeutic pairs of new or already-existing drugs. This protocol is simple, robust and can be completed within a 1-week working period.


siRNA library screening Triple-negative breast cancer cells siRNA transfection 



B.T. was supported by Alberta Innovates Graduate Studentship. The authors RBKC and HU are the founder and shareholders in RJH Biosciences Inc. that are developing the lipopolymers for medical applications.


  1. 1.
    McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3(10):737–747. Scholar
  2. 2.
    Aliabadi HM, Maranchuk R, Kucharski C, Mahdipoor P, Hugh J, Uludag H (2013) Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. J Control Release 172(1):219–228. Scholar
  3. 3.
    Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA, Lieberman J (2013) A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24(2):182–196. Scholar
  4. 4.
    Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A 109(8):2730–2735. Scholar
  5. 5.
    Thapa B, Bahadur Kc R, Uludag H (2018) Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery. Int J Cancer 142(3):597–606. Scholar
  6. 6.
    Parmar MB, Meenakshi Sundaram DN, Kaur H, KC RB, Maranchuk R, Aliabadi HM, Hugh JC, Löbenberg R, Uludağ H (2018) Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomater 66:294–309CrossRefPubMedGoogle Scholar
  7. 7.
    Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H (2015) Targeting cell cycle proteins in breast cancer cells with siRNA by using lipid-substituted polyethylenimines. Front Bioeng Biotechnol 3:14CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5(5):1136–1144. Scholar
  9. 9.
    Muller R (2004) Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol 130(8):429–444. Scholar
  10. 10.
    K CR, Thapa B, Valencia-Serna J, Aliabadi HM, Uludag H (2017) Nucleic acid combinations: a new frontier for cancer treatment. J Control Release 256:153–169. Scholar
  11. 11.
    Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5(8):649–659. Scholar
  12. 12.
    Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, Li YX, Chen YZ (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8(2):111–128. Scholar
  13. 13.
    Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689–698. Scholar
  14. 14.
    Hsu CY, Uludag H (2012) A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine. Nat Protoc 7(5):935–945. Scholar
  15. 15.
    Meenakshi Sundaram DN, Kucharski C, Parmar MB, Kc RB, Uludag H (2017) Polymeric delivery of siRNA against Integrin-beta1 (CD29) to reduce attachment and migration of breast cancer cells. Macromol Biosci 17(6). Scholar
  16. 16.
    Brunner S, Sauer T, Carotta S, Cotten M, Saltik M, Wagner E (2000) Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther 7(5):401–407. Scholar
  17. 17.
    Izumisawa T, Hattori Y, Date M, Toma K, Maitani Y (2011) Cell line-dependent internalization pathways determine DNA transfection efficiency of decaarginine-PEG-lipid. Int J Pharm 404(1–2):264–270. Scholar
  18. 18.
    Douglas KL, Piccirillo CA, Tabrizian M (2008) Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 68(3):676–687. Scholar
  19. 19.
    Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE (2009) Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6(8):569–575. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Faculty of Pharmacy and Pharmaceutical SciencesUniversity of AlbertaEdmontonCanada
  2. 2.Department of Chemical and Material Engineering, Faculty of EngineeringUniversity of AlbertaEdmontonCanada
  3. 3.Department of Biomedical Engineering, Faculty of Medicine and DentistryUniversity of AlbertaEdmontonCanada

Personalised recommendations